entire C suite leaving in general not a good sign,especially just when the rubber is about to hit the road
In addition to the CEO and CFO, the CMO also left last year. Seems really hard to take any positive sign out of all these departures. I had to sell out end of last year for tax reasons but had plans to potentially get back in. I won't be doing so now after this latest departure.
I do wonder if there's any potential positive read-through to the other CRISPR players like CRSP or if this is potentially a negative broad read-through for the entire field (my gut is the latter).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.